Correlation between serum METRNL，sTREM-1 levels and carotid atherosclerosis in type 2 diabetes mellitus patients

doi:10.3969/j.issn.1673-8640.2024.10.007

Abstract

Abstract:

Objective To investigate the correlation between serum meteorin-like protein（METRNL），soluble triggering receptor expression on myeloid cell-1（sTREM-1） levels and the degree of carotid atherosclerosis（CAS） in patients with type 2 diabetes mellitus（T2DM）. Methods A total of 235 T2DM patients from Chengde Central Hospital from December 2021 to December 2023 were enrolled. T2DM patients were classified into CAS group（126 cases） and control group（109 cases） based on whether they had CAS. The clinical data and laboratory determination results were collected，and the levels of serum METRNL and sTREM-1 were determined. Spearman method was used to analyze the correlation between serum METRNL，sTREM-1 levels and the degree of CAS. Multivariate Logistic regression was used to analyze the factors for the degree of CAS. Results Compared with control group，serum METRNL level in CAS group was decreased（P<0.05），while serum sTREM-1 level was increased（P<0.05）. Serum METRNL level in IMT thickening group，plaque formation group and carotid artery stenosis group were decreased in turn（P<0.001），while sTREM-1 level was increased in turn（P<0.001）. There was a negative correlation between serum METRNL and the severity of CAS in CAS patients（r_s=-0.422，P<0.05），and there was a positive correlation between sTREM-1 and the severity of CAS（r_s=0.535，P<0.05）. History of hypertension，sTREM-1，glycated hemoglobin A_1c（HbA_1c） and low-density lipoprotein cholesterol（LDL-C） were risk factors for CAS severity （carotid artery stenosis） [odds ratios（OR） were 3.354，2.165，1.642 and 1.943，95% confidence intervals（CI） were 1.580-7.119，1.296-3.618，1.238-2.177 and 1.188-3.178]，and METRNL was a protective factor（OR=0.768，95%CI 0.640-0.922，P<0.05）. Conclusions Serum METRNL level is decreased and sTREM-1 level is increased in T2DM patients with CAS，which is related to the degree of CAS.

Key words: Meteorin-like protein, Soluble triggering receptor expression on myeloid cell-1, Type 2 diabetes mellitus, Carotid atherosclerosis

CLC Number:

R446.1

TIAN Na, CHEN Shihong, YANG Tao. Correlation between serum METRNL，sTREM-1 levels and carotid atherosclerosis in type 2 diabetes mellitus patients[J]. Laboratory Medicine, 2024, 39(10): 963-968.

Figures/Tables 6

References 26

[1]	陈一文, 张雪莲. 2型糖尿病患者发生颈动脉粥样硬化与增殖期糖尿病视网膜病变的相关性研究[J]. 中国全科医学, 2022, 25(23):2843-2848. DOI
[2]	王中群. 重视糖尿病大血管并发症的发病、机制、评估与防治研究[J]. 中南医学科学杂志, 2022, 50(1):1-6.
[3]	MÉNÉGAUT L, LAUBRIET A, CRESPY V, et al. Inflammation and oxidative stress markers in type 2 diabetes patients with advanced carotid atherosclerosis[J]. Cardiovasc Diabetol, 2023, 22(1):248. DOI PMID
[4]	高素颖, 颜应琳, 于凯, 等. 急性缺血性脑卒中颈动脉粥样硬化的危险因素研究[J]. 中国全科医学, 2021, 24(3):327-332. DOI
[5]	赵郁松, 梅笑雪. 2型糖尿病患者血清S100A12、sRAGE与颈动脉内膜中层厚度的相关性研究[J]. 国际检验医学杂志, 2022, 43(9):1138-1141.
[6]	FADAEI R, DADMANESH M, MORADI N, et al. Serum levels of subfatin in patients with type 2 diabetes mellitus and its association with vascular adhesion molecules[J]. Arch Physiol Biochem, 2020, 126(4):335-340. DOI PMID
[7]	HANBEYOGLU O, AYDIN S. Subfatin,asprosin,alamandine and maresin-1 inflammation molecules in cardiopulmonary bypass[J]. J Inflamm Res, 2023, 16:3469-3477.
[8]	LI Z Y, ZHENG S L, WANG P, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression[J]. CNS Neurosci Ther, 2014, 20(4):344-354.
[9]	周欣峰, 戚韶红, 周俊文, 等. 血清sTREM-1对下肢动脉硬化闭塞症支架植入术后血管再狭窄的预测价值[J]. 山东医药, 2020, 60(10):18-22.
[10]	DIMOPOULOU I, PELEKANOU A, MAVROU I, et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients:correlation with monocyte gene expression[J]. J Crit Care, 2012, 27(3):294-300.
[11]	GIBOT S, CRAVOISY A, LEVY B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia[J]. N Engl J Med, 2004, 350(5):451-458.
[12]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J]. 中国实用内科杂志, 2021, 41(8):668-695.
[13]	中国医师协会超声医师分会. 血管和浅表器官超声检查指南[M]. 北京: 人民军医出版社, 2011.
[14]	王庆, 虞寒芬, 陈萍. 2型糖尿病患者继发颈动脉粥样硬化的危险因素分析[J]. 现代实用医学, 2021, 33(7):923-924.
[15]	李茗茗, 冯斌, 吴梦娇, 等. 2型糖尿病155例血清肌腱蛋白C水平与颈动脉粥样硬化的相关性分析[J]. 安徽医药, 2023, 27(10):1970-1975.
[16]	MA A, HE M, BAI J, et al. Dual role of insulin in spexin regulation:functional link between food intake and spexin expression in a fish model[J]. Endocrinology, 2017, 158(3):560-577.
[17]	ONALAN E, CAVLI C, DOGAN Y, et al. Low serum levels of meteorin-like/subfatin:an indicator of diabetes mellitus and insulin resistance?[J]. Endokrynol Pol, 2020, 71(5):397-403.
[18]	YAVUZKIR S, UGUR K, DENIZ R, et al. Maternal and umbilical cord blood subfatin and spexin levels in patients with gestational diabetes mellitus[J]. Peptides, 2020, 126:170277.
[19]	刘翠明, 马学芹, 唐正和, 等. 糖尿病视网膜病变患者血清Metrnl和鸢尾素水平变化及其临床意义[J]. 眼科新进展, 2022, 42(6):469-473.
[20]	廖勇, 郭一雲, 周红宇, 等. 血清subfatin与2型糖尿病患者微血管病变的相关性分析[J]. 华南国防医学杂志, 2021, 35(10):712-715.
[21]	DADMANESH M, AGHAJANAI H, FADAEI R, et al. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines[J]. PLoS One, 2018, 13(9):e0204180.
[22]	LI C, ZHU L, GONG X, et al. Soluble triggering receptor expressed on myeloid cells-1 as a useful biomarker for diagnosing ventilator-associated pneumonia after congenital cardiac surgery in children[J]. Exp Ther Med, 2019, 17(1):147-152. DOI PMID
[23]	翁海美, 许花芬, 蔡冬, 等. 新生儿感染性肺炎血清sTREM-1水平与炎性因子、免疫球蛋白的相关性分析[J]. 疑难病杂志, 2019, 18(4):353-357.
[24]	仇正锋, 顾勤, 刘宁, 等. 可溶性髓系细胞触发受体1对呼吸机相关性肺炎的早期诊断价值[J]. 中国呼吸与危重监护杂志, 2014, 13(1):105-107.
[25]	RAO V H, RAI V, STOUPA S, et al. Tumor necrosis factor-α regulates triggering receptor expressed on myeloid cells-1-dependent matrix metalloproteinases in the carotid plaques of symptomatic patients with carotid stenosis[J]. Atherosclerosis, 2016, 248:160-169. DOI PMID
[26]	田浩, 郑翔, 闻作川, 等. ASO患者血管介入术后ET-1、sTREM-1、VEGF水平对血管再狭窄发生的预测价值[J]. 中国病案, 2023, 24(1):106-109.

组别	例数	年龄/岁	性别		糖尿病病程/年	高血压史/ [例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	糖尿病病程/年	高血压史/ [例（%）]
CAS组	126	58.64±7.46	67（53.17）	59（46.83）	4.98±1.21	58（46.03）
对照组	109	59.24±7.51	51（46.79）	58（53.21）	4.79±1.18	49（44.95）
统计值		0.613	0.953		1.214	0.027
P值		0.541	0.329		0.226	0.869
组别	高血脂史/[例（%）]	心率/（次·min^-1）	收缩压/kPa	舒张压/kPa	FBG/（mmol·L^-1）	HbA_1c/%
CAS组	54（42.86）	74.64±3.75	16.41±1.35	9.32±1.15	8.34±1.46	5.67±1.29
对照组	43（39.45）	73.89±3.43	16.21±1.29	9.50±0.99	8.15±1.41	5.59±1.26
统计值	0.280	1.590	1.156	1.276	1.011	0.479
P值	0.597	0.113	0.249	0.203	0.313	0.632
组别	FINS/（mIU·L^-1）	TC/（mmol·L^-1）	TG/（mmol·L^-1）	LDL-C/（mmol·L^-1）		HDL-C/（mmol·L^-1）
CAS组	18.91±3.05	4.79±1.04	1.52±0.31	3.41±0.61		1.55±0.42
对照组	18.75±2.84	4.62±1.02	1.47±0.23	3.35±0.64		1.62±0.43
统计值	0.414	1.261	1.386	0.735		1.260
P值	0.679	0.209	0.167	0.463		0.209

组别	例数	年龄/岁	性别		糖尿病病程/年	高血压史/ [例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	糖尿病病程/年	高血压史/ [例（%）]
CAS组	126	58.64±7.46	67（53.17）	59（46.83）	4.98±1.21	58（46.03）
对照组	109	59.24±7.51	51（46.79）	58（53.21）	4.79±1.18	49（44.95）
统计值		0.613	0.953		1.214	0.027
P值		0.541	0.329		0.226	0.869
组别	高血脂史/[例（%）]	心率/（次·min^-1）	收缩压/kPa	舒张压/kPa	FBG/（mmol·L^-1）	HbA_1c/%
CAS组	54（42.86）	74.64±3.75	16.41±1.35	9.32±1.15	8.34±1.46	5.67±1.29
对照组	43（39.45）	73.89±3.43	16.21±1.29	9.50±0.99	8.15±1.41	5.59±1.26
统计值	0.280	1.590	1.156	1.276	1.011	0.479
P值	0.597	0.113	0.249	0.203	0.313	0.632
组别	FINS/（mIU·L^-1）	TC/（mmol·L^-1）	TG/（mmol·L^-1）	LDL-C/（mmol·L^-1）		HDL-C/（mmol·L^-1）
CAS组	18.91±3.05	4.79±1.04	1.52±0.31	3.41±0.61		1.55±0.42
对照组	18.75±2.84	4.62±1.02	1.47±0.23	3.35±0.64		1.62±0.43
统计值	0.414	1.261	1.386	0.735		1.260
P值	0.679	0.209	0.167	0.463		0.209

组别	例数	METRNL/（pg·mL^-1）	sTREM-1/（ng·L^-1）
CAS组	126	68.98±18.38	312.69±58.66
对照组	109	94.01±22.21	248.04±45.23
t值		9.451	9.350
P值		<0.001	<0.001

组别	例数	METRNL/（pg·mL^-1）	sTREM-1/（ng·L^-1）
CAS组	126	68.98±18.38	312.69±58.66
对照组	109	94.01±22.21	248.04±45.23
t值		9.451	9.350
P值		<0.001	<0.001

组别	例数	METRNL/（pg·mL^-1）	sTREM-1/（ng·L^-1）
IMT增厚组	26	87.46±20.56	254.12±44.24
斑块形成组	41	68.63±18.61^*	287.45±58.63^*
颈动脉狭窄组	59	61.08±17.25^*#	356.04±56.22^*#
F值		18.542	37.621
P值		<0.001	<0.001